中央型及超中央型原发性肺肿瘤立体定向消融放疗后十年结局
单中心研究纳入2008至2015年接受VMAT治疗的127例中央型原发性或复发性肺癌患者,60 Gy分8或12次照射。5年重度临床支气管毒性发生率为34.1%,影像学支气管毒性为37.5%;肿瘤距气管或主支气管≤1 cm及体能状态评分2至3分是重度临床毒性的显著预测因素。
要点
- 中央型肺肿瘤SABR后5年重度临床支气管毒性发生率为34.1%(95%CI 21.2-44.9)。
- 肿瘤距气管或主支气管≤1 cm者重度临床毒性风险显著升高(HR 4.3;95%CI 1.2-14.9)。
- 体能状态评分2或3分是重度临床毒性的显著预测因素(HR 3.6;95%CI 1.7-7.8)。
核心结论
- 中央型SABR后存活5年的患者中,重度临床和影像学支气管毒性的实际发生率均约为35%。
- 肿瘤位于距气管或主支气管≤1 cm的患者重度临床毒性风险最高。
研究设计与样本
- 单中心研究,2008至2015年接受VMAT治疗的中央型原发性或复发性肺癌患者。
- 60 Gy分8或12次照射,随访≥2年,共127例 eligible 患者纳入分析。
主要发现
- 127例中63%接受8次分割治疗;中位肿瘤直径4.4 cm(范围1.3-12.0)。
- 中位总生存期25.0个月(95%CI 16.5-33.5);4%出现孤立局部复发。
- 重度临床毒性5年实际发生率为34.1%(95%CI 21.2-44.9)。
- 影像学支气管毒性5年实际发生率为37.5%(95%CI 21.5-50.2)。
- 临床毒性和致命性肺出血最常见于肿瘤距气管或主支气管≤1 cm者(占全部病例的46%)。
关键数值与推荐
- 多变量分析显示体能状态评分2或3分(HR 3.6;95%CI 1.7-7.8)和肿瘤距气管或主支气管≤1 cm(HR 4.3;95%CI 1.2-14.9)是重度临床毒性的显著预测因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: SABR performed for central and ultracentral lung tumors is associated with increased toxicity but limited data is available on late toxicities. We studied toxicity in patients followed-up ≥ 2 years post-SABR at a single-institution. METHODS: All patients were treated using VMAT for a primary or recurrent central lung cancer between 2008-2015. 60 Gy was delivered in 8 or 12 fractions. Grade ≥ 3 clinical and radiological bronchial toxicity was scored. Multivariable Cox regression models were used to estimate hazard ratios. RESULTS: Of 127 eligible patients, 63% were treated with 8 fractions. Median tumor diameter was 4.4 cm (range 1.3-12.0). Median overall survival was 25.0 months (95% CI 16.5-33.5); 4% developed isolated local recurrences. The actuarial 5-year rate for severe clinical toxicity was 34.1% (95% CI 21.2-44.9). Both clinical toxicity and fatal lung haemorrhage were most observed when tumors were located ≤ 1 cm from the trachea or main bronchi (46% of all cases). The 5-year actuarial rate of radiological bronchial toxicity was 37.5% (95% CI 21.5-50.2). Multivariable analysis revealed that a performance score of 2 or 3 (HR 3.6; 95% CI 1.7-7.8), and tumor location ≤ 1 cm from the trachea or main bronchi (HR 4.3; 95% CI 1.2-14.9) were significant predictors for severe clinical toxicity. CONCLUSION: The actuarial rates for both severe clinical and radiological bronchial toxicity after central SABR was approximately 35% in patients surviving 5 years. Patients with tumors located ≤ 1 cm from the trachea or main bronchus were at the highest risk for severe clinical toxicity.
引用
- Tekatli H, Giraud N, van Eekelen R, et al. Ten years outcomes after SABR in central and ultracentral primary lung tumors. Radiother Oncol. 2023. PMID: 37562553. doi:10.1016/j.radonc.2023.109848
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。